

### **AMENDMENTS TO THE CLAIMS**

Please cancel originally filed claims 1-10 and substitute therefor the new claims presented below (i.e., Claims 11 - 27). The text and status of all of the claims following entry of these amendments will be as follows:

Claims 1-10 (cancelled)

Claim 11 (new) A method of treating ophthalmic infections, which comprises topically applying to the eye a therapeutically effective amount of a pharmaceutical composition comprising an antimicrobial effective amount of moxifloxacin or a pharmaceutically useful hydrate or salt thereof and a pharmaceutically acceptable vehicle therefor.

Claim 12 (new) A method according to claim 11, wherein the composition further comprises a steroidal or non-steroidal anti-inflammatory agent.

Claim 13 (new) A method according to claim 12, wherein the anti-inflammatory agent comprises a steroidal agent.

Claim 14 (new) A method according to claim 13, wherein the steroidal agent comprises a glucocorticoid.

Claim 15 (new) A method according to claim 14, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone, budesonide, and combinations thereof.

Claim 16 (new) A method according to claim 14, wherein the glucocorticoid comprises dexamethasone.

Claim 17 (new) A method according to claim 14, wherein the glucocorticoid comprises a 21-ether derivative of dexamethasone.

Claim 18 (new) A method according to claim 14, wherein the glucocorticoid comprises a 21-benzyl ether derivative of dexamethasone.

Claim 19 (new) A method according to claim 12, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, cyclooxygenase type II selective inhibitors, PAF antagonists, PDE IV inhibitors, and combinations thereof.

Claim 20 (new) A method according to claim 19, wherein the non-steroidal agent comprises a prostaglandin H synthetase inhibitor.

Claim 21 (new) A method according to claim 20, wherein the prostaglandin H synthetase inhibitor comprises nepafenac.

Claim 22 (new) A method according to claim 20, wherein the prostaglandin H synthetase comprises ketorolac.

Claim 23 (new) A method according to claim 20, wherein the prostaglandin H synthetase comprises diclofenac.

Claim 24 (new) A method according to claim 19, wherein the non-steroidal agent comprises a cyclooxygenase type II selective inhibitor.

Claim 25 (new) A method according to claim 11, wherein the composition is applied to the eye in connection with the treatment of a condition selected from the group consisting of conjunctivitis, keratitis, blepharitis, dacryocystitis, hordeolum, corneal ulceration, and combinations thereof.

Claim 26 (new) A method according to any one of claims 11-25, wherein the composition contains moxifloxacin at a concentration of 0.1 to 1.0 wt. %. 15

Claim 27 (new) A method according to any one of claims 11-24, wherein the composition is applied to the eye in connection with an ophthalmic surgical procedure. 13